What YiShu Treats: Main Uses and Benefits

YiShu (Pentoxifylline) is generally used in clinical settings marked by chronic occlusive vascular disorders in conditions associated with increased physiological stress and interference with daily functioning. Its core therapeutic use is relevant in conditions characterized by periods of heightened symptoms.

The medication is commonly applied in scenarios where short-term symptomatic assistance is needed to address the pain, aching, or cramping in the legs that occurs during walking (Intermittent Claudication). It may also be part of symptomatic management in situations like chronic venous leg ulcers. The primary therapeutic benefit may assist with functional stability in situations where walking is affected, which supports patients during difficult episodes and contributes to improved day-to-day comfort.

This medication is considered relevant in conditions presenting with systemic or localized discomfort in the lower extremities, providing supportive relief that may assist with maintaining functional stability and helping to ease the overall symptom burden.

---

Quick Fact: Symptomatic Relief YiShu is relevant for easing symptoms that interfere with daily comfort, specifically the pain and functional strain caused by symptoms that create noticeable physiological strain.

The eligibility profile for YiShu (Pentoxifylline) is strictly defined by regulatory authorities based on age, physiological status, and contraindications. Use is approved for adult patients (18 years and older).

Absolute Contraindications: The medicine is prohibited for patients with known hypersensitivity to pentoxifylline or related methylxanthines. Use must also be avoided by those with recent cerebral or extensive retinal hemorrhage, a history of peptic ulcers, or a recent acute myocardial infarction.

Restricted and Non-Eligible Groups: YiShu is generally not recommended for the pediatric population (under 18 years) because its safety and effectiveness have not been established. Due to the risk of drug accumulation, the medicine is also not recommended in cases of severe renal impairment or severe hepatic impairment. Use requires caution in older adult patients and those with conditions that pose a risk of bleeding.

Pregnancy and Lactation: For pregnancy (Category C), use is generally not recommended. Since the drug is excreted into human milk, regulatory guidance advises the mother to discontinue either the drug or nursing.

The interaction profile for Pentoxifylline, as documented by regulatory authorities, centers on potential additive pharmacodynamic effects and specific metabolic clearance pathways. The co-administration with other methylxanthines is formally contraindicated due to the risk of cross-hypersensitivity or intolerance to xanthine derivatives. The regulatory status also notes that co-administration with Ketorolac is not recommended.

Pharmacokinetic Interactions

The metabolic clearance of Pentoxifylline and its active metabolites is susceptible to interference by other substances. Strong CYP1A2 inhibitors, such as Ciprofloxacin or Cimetidine, are officially noted to increase the systemic exposure (AUC and Cmax) of Pentoxifylline and its Metabolite I due to reduced metabolic clearance.

Pharmacodynamic and Clinical Effects

Due to the product's influence on blood properties, caution is needed with medicines that affect coagulation. Concomitant use with Anticoagulants (e.g., Warfarin) or Platelet Aggregation Inhibitors (e.g., Aspirin) has been associated with an increased risk of bleeding and/or prolonged prothrombin time. Furthermore, the effects of certain Antihypertensive Drugs or Antidiabetic Agents may be potentiated by Pentoxifylline, resulting in enhanced lowering of blood pressure or blood glucose, requiring monitoring procedures.

Specific Constraints and Population Considerations

Regulatory documents specify that the risk of toxic reactions may be greater in patients with Renal Impairment due to significantly increased exposure to active metabolites. The co-administration of the medication with a meal results in a minor, documented increase in the plasma concentrations of Pentoxifylline.

Hemorheologic Optimization via Enzyme Inhibition

The drug's primary action begins with the inhibition of Phosphodiesterase (PDE) enzymes, leading to an increase in the intracellular concentration of the messenger cyclic adenosine monophosphate (cAMP) within key blood cells. This molecular step directly enhances the deformability and flexibility of erythrocytes (red blood cells) and reduces their rigidity. This mechanism fundamentally lowers the viscosity of the whole blood, which facilitates the flow of blood through narrow segments of the microcirculation .

Modulation of Inflammatory Cell Function

Complementary to its effect on viscosity, Pentoxifylline modulates the function of other circulatory components. The mechanism suppresses the activation and adhesion of leukocytes (white blood cells) to vessel walls and inhibits the production of key pro-inflammatory mediators such as Tumor Necrosis Factor-alpha (TNF-alpha). The mechanism contributes to decreased adhesion and activation of cells that influence vascular flow dynamics, which results in enhanced delivery of blood volume to the capillary network. The combined effects promote altered flow properties of cellular elements within the capillaries.

Administration Guidelines for YiShu (Pentoxifylline 400 mg ER Tablet)

The use of YiShu follows specific instructions for administration.

Category	Instruction
Route of Administration	Oral administration.
Dosing Schedule	The usual starting dose is 400 mg three times daily (TID). The dose may be lowered to 400 mg two times daily (BID) if certain systemic effects are observed.
Timing in Relation to Meals	Must be taken with meals or immediately after meals to support patient tolerance.
Preparation Requirements	The extended-release tablet must be swallowed whole with a drink and must not be crushed, broken, or chewed.

---

Use in Specific Populations

Dose adjustments apply in patients with impaired organ function. In patients with severe renal impairment (creatinine clearance below 30 mL/min), the dose is adjusted to 400 mg once a day. Similarly, cautious dose adjustment is required for patients with hepatic impairment. The medication is not established for use in the pediatric population (patients under 18 years of age).

Procedural Directives

Treatment should be continued for a minimum of 8 weeks to adequately assess the course of use. If a dose is missed, the general directive is to take it as soon as possible, or skip it entirely if it is near the time for the next scheduled dose; doses must never be doubled. The overall protocol establishes a daily dosing frequency that is strictly linked to the tablet's integrity and meal timing.

Research evidence / Overview of Studies for YiShu

Evidence for Use in Intermittent Claudication

YiShu (Pentoxifylline) was studied for its use in studies examining symptoms related to the leg pain and cramping associated with walking (intermittent claudication). The research primarily consists of Randomized Controlled Trials (RCTs), where the medicine was compared against a placebo (an inactive pill). Researchers monitored outcomes reflecting daily functioning or activity level, specifically measuring Pain-Free Walking Distance (PFWD) and Total Walking Distance (TWD) on a standardized treadmill test.

Studies conducted during periods of increased symptom activity generally examined measurements of walking distance compared to the placebo groups. Research highlights changes measured during the study period which was observed in some studies. Systematic reviews noted that findings were mixed across different trials. Certainty remains low, which is influenced by the fact that sample sizes were modest in many trials, and follow-up durations were limited (often six months or less).

Evidence for Use in Chronic Venous Leg Ulcers (Adjunctive Therapy)

The medicine was evaluated in the context of conditions marked by functional limitations, specifically as an added therapy for chronic venous leg ulcers. The studies primarily examined outcomes related to adding YiShu to standard treatment, such as compression therapy, specifically in relation to healing measurements. Research examined outcomes such as the proportion of patients achieving complete ulcer healing and the time it took for the wounds to close.

Trials in this area reported measurements of differences in the rate of complete ulcer closure for patients receiving the medicine plus compression therapy, compared to those receiving compression therapy alone. The study design makes the precise, independent measured difference challenging to isolate, as its role is documented as an adjunctive treatment. Additionally, long-term effects are not fully established regarding whether the medication can influence the rate at which ulcers return (recurrence).

What is Still Uncertain About the Research for YiShu

The authoritative scientific literature highlights several key gaps where certainty remains low or where more research is needed. First, comparative evidence is lacking to firmly establish how YiShu compares to modern, non-pharmacological interventions like structured exercise programs for walking. Second, long-term effects are not fully established, particularly concerning the influence on major health outcomes over a period of several years. This evidence highlights what is known—and what is still uncertain—in the broader research landscape.

Key Studies & References

1. Peripheral arterial disease: diagnosis and management (NICE Guideline CG147)
2. Pentoxifylline - StatPearls - NCBI Bookshelf (General Monograph/Review)

Common questions about YiShu (FAQ)

Q: What is the typical timeframe or duration for treatment with YiShu (Pentoxifylline)?

A: Official product information suggests that effects may be observed within two to four weeks. Regulatory documents indicate that a minimum of 8 weeks of treatment is often assessed to determine the course of use and evaluate its efficacy.

---

Q: If I am taking blood pressure medication, do I need to be concerned about drug interactions with YiShu?

A: Regulatory documents indicate that YiShu (Pentoxifylline) may potentiate (meaning it could enhance or increase) the effects of certain antihypertensive drugs. Due to this potential for enhanced blood pressure lowering, official sources state that monitoring procedures may be necessary when these medicines are used together.

---

Q: What should I do if I am pregnant or breastfeeding while taking YiShu?

A: Official prescribing information states that the drug is generally not recommended during pregnancy. The regulatory guidance for breastfeeding indicates that since the drug is excreted into human milk, discontinuation of either the drug or nursing is advised.

---

Q: Why is my dose of YiShu lower than 400 mg three times daily?

A: According to official sources, the dose may be lowered from three times daily to twice daily if certain side effects, particularly those affecting the digestive tract or nervous system, are observed. The dose is also specifically reduced in patients who have severe renal impairment (poor kidney function) to account for drug accumulation.

---

Q: What is the maximum daily dose of YiShu (Pentoxifylline) that can be taken?

A: The official product labeling for the extended-release tablet specifies that the recommended starting and maximum daily dose is 400 mg three times a day (total 1200 mg/ day). This dosage is documented in official regulatory documents as the recommended maximum daily dose.

---

Q: How long do the effects of YiShu last after I take a dose?

A: Studies noted in regulatory documents show that the parent drug, Pentoxifylline, has a short half-life in the bloodstream, typically under an hour. However, the active metabolites that contribute to its therapeutic effects have a longer half-life (around 1 to 1.6 hours). The extended-release formulation is designed to release the medication slowly to sustain the drug's effect over a longer period.

---

Q: Is there a generic version of YiShu (Pentoxifylline) available?

A: Yes, the active ingredient in YiShu, which is Pentoxifylline, is approved and available as a generic extended-release oral tablet in various regions. The availability of a generic version may depend on your local pharmaceutical regulations.

---

Q: What should I avoid eating or drinking while I am taking YiShu?

A: Official product information notes a contraindication—a formal restriction—against taking this medication with other methylxanthines. This class of substance includes compounds like theophylline, caffeine, and theobromine, and the restriction is due to the potential risk of cross-hypersensitivity or intolerance.

How to Store and Dispose of YiShu (Pentoxifylline)

Storage Requirements

YiShu (Pentoxifylline extended-release tablets) must be stored at Controlled Room Temperature, which is defined as 20°C to 25°C (68°F to 77°F). Temperature excursions are permitted between 15°C and 30°C. The tablets must be kept in a tightly closed container to ensure product stability and integrity. As with all medications, YiShu must be stored out of the sight and reach of children.

Disposal Instructions

To prevent environmental contamination, unused or expired YiShu tablets must not be flushed down a toilet or poured down a drain. The medication should be disposed of by mixing it with an unappealing substance, sealing it in a plastic bag, and placing it in the household trash, or by utilizing an authorized drug take-back program. Pentoxifylline is not classified as hazardous cytotoxic waste.